Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

被引：28
|
作者：
Schmid, P. [1 ]
Jung, K. H. [2 ]
Wysocki, P. J. [3 ]
Jassem, J. [4 ]
Ma, C. X. [5 ]
Fernandes, R. [6 ]
Huisden, R. [7 ]
Stewart, R. [8 ]
Vukovic, P. [9 ]
Nunes, A. Tablante [10 ]
Nowecki, Z. [11 ]
机构：
[1] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, London, England
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Jagiellonian Univ Med Coll, Dept Oncol, Krakow, Poland
[4] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[5] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
[6] Western Univ, London Hlth Sci Ctr, Div Med Oncol, Dept Oncol,Schulich Sch Med & Dent, London, ON, Canada
[7] AstraZeneca, Stat, Cambridge, England
[8] AstraZeneca, Translat Med, Oncol, Cambridge, England
[9] AstraZeneca, Late Dev Oncol, Cambridge, England
[10] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[11] Maria Sklodowska Curie Natl Res Inst Oncol, Breast Surg, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166MO
引用
收藏
页码：S199 / S199
页数：1
相关论文
共 50 条
  • [1] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
    Schmid, P.
    Wysocki, P. J.
    Ma, C. X.
    Park, H.
    Fernandes, R.
    Lord, S.
    Baird, R. D.
    Prady, C.
    Jung, K. H.
    Asselah, J.
    Huisden, R.
    Stewart, R.
    Heider, K.
    Vukovic, P.
    Denduluri, N.
    Nowecki, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S337 - S337
  • [2] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study
    Schmid, Peter
    Wysocki, Piotr
    Ma, Cynthia
    Park, Yeon H.
    Fernandes, Ricardo
    Lord, Simon
    Baird, Richard D.
    Prady, Catherine
    Jung, Kyung Hae
    Asselah, Jamil
    Huisden, Robert
    Stewart, Ross
    Vukovic, Petra
    Nunes, Ana T.
    Nowecki, Zbigniew
    CANCER RESEARCH, 2023, 83 (05)
  • [3] AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab plus Carboplatin as 1L Treatment of Advanced/mNSCLC
    Aggarwal, C.
    Cheema, P.
    Arrieta, O.
    Bonanno, L.
    Borghaei, H.
    Hu, Y.
    Kim, D. -W.
    de Castro Junior, G.
    Hepner, A.
    Deng, C.
    del Riego, M. Gonzalez
    Kato, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S305 - S306
  • [4] Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
    Bardia, Aditya
    Krop, Ian
    Meric-Bernstam, Funda
    Tolcher, Anthony W.
    Mukohara, Toru
    Lisberg, Aaron
    Shimizu, Toshio
    Hamilton, Erika
    Spira, Alexander I.
    Papadopoulos, Kyriakos P.
    Greenberg, Jonathan
    Gu, Wen
    Kobayashi, Fumiaki
    Zebger-Gong, Hong
    Kawasaki, Yui
    Wong, Rie
    Kogawa, Takahiro
    CANCER RESEARCH, 2023, 83 (05)
  • [5] BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).
    Schmid, Peter
    Nunes, Ana Tablante
    Dry, Hannah
    Dougherty, Rachel
    Karwe, Vatsala
    Scheuring, Urban J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
    Alhalabi, Omar
    Meric-Bernstam, Funda
    Lisberg, Aaron
    Drakaki, Alexandra
    Garmezy, Benjamin
    Kogawa, Takahiro
    Spira, Alexander I.
    Salkeni, Mohamad Adham
    Gao, Xin
    Tolcher, Anthony W.
    Bhave, Manali A.
    Doroshow, Deborah Blythe
    Hoffman-Censits, Jeannie
    Klauss, Gunnar
    Kaga, Yoshiaki
    Kakurai, Yasuyuki
    Kojima, Takahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [7] Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04
    Papadopoulos, K. P.
    Bruno, D.
    Kitazono, S.
    Murakami, S.
    Gutierrez, M.
    Wakuda, K.
    Spira, A.
    Cuppens, K.
    Lovick, S.
    Hepner, A.
    Mak, G.
    Waqar, S. N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S55 - S55
  • [8] Trastuzumab deruxtecan (T-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR-), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study
    Schmid, Peter
    Wysocki, Piotr
    Park, Yeon H.
    Jassem, Jacek
    Jung, Kyung Hae
    Lord, Simon
    Huisden, Robert
    Stewart, Ross
    Vukovic, Petra
    Nunes, Ana T.
    Nowecki, Zbigniew
    CANCER RESEARCH, 2023, 83 (05)
  • [9] ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
    De Langen, J.
    Cho, B. C.
    Piotrowska, Z.
    Le, X.
    Goldberg, S. B.
    Goldman, J. W.
    Okamoto, I.
    Hewson, N.
    Maidment, J.
    Tang, K. H.
    Veney, N.
    Cosaert, J.
    Lau, J.
    Dressman, M.
    Ambrose, H.
    Riess, J. W.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1091 - S1092
  • [10] COST-EFFECTIVENESS OF PEMBROLIZUMAB PLUS CHEMOTHERAPIES FOR FIRST-LINE TREATMENT IN LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN FRANCE
    Tredan, O.
    Bensimon, L.
    Apert, M.
    Tehard, B.
    Carita, M.
    Khandelwal, A.
    Gandhi, J.
    Haiderali, A.
    Huang, M.
    Levy, P.
    VALUE IN HEALTH, 2022, 25 (12) : S54 - S55
12345